Jakob Ribbing, Ph.D.

Principal Consultant & Client Operations Expert

Bio

  • Joined Pharmetheus in 2014, actively working in client and internal projects/roles, and serving as Client Operations Expert and Deputy Project Portfolio Team Leader
  • Expertise includes pharmacometrics, model-informed drug development, model based meta analysis, and pediatrics in therapeutic areas such as allergy, inflammation, respiratory, neuroscience, oncology and diabetes
  • Previously worked as Associate Director in Pharmacometrics at Pfizer in UK and Sweden, where he was responsible for team interaction and pharmacometrics deliveries for the Pfizer Allergy and Respiratory portfolio, as well as support to Pfizer global pharmacometrics and clinical pharmacology, and as Manager in Pharmacometrics at Pfizer INC, UK
  • M.Sc. in Pharmacy (2001) and Ph.D. in Biopharmaceutical Sciences (2007) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Covariate modeling in pharmacometrics: General points for considerationPredicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1 – A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical TrialsTranslating Pharmacometrics to a Pharmacoeconomic Model of COPDUse of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysisPopulation Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients with Severe AsthmaPopulation pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis [2]Population Pharmacokinetic Analysis of Etrolizumab in Patients with Moderately-to-Severely Active Ulcerative ColitisPopulation Repeated Time-to-Event Analysis of Exacerbations in Asthma Patients: A Novel Approach for Predicting Asthma Exacerbations Based on Biomarkers, Spirometry, and Diaries/QuestionnairesPopulation RTTE Analysis of Exacerbations in Asthma Patients: a Novel Approach for Predicting Asthma Exacerbations Based on Biomarkers, Spirometry and Diaries/QuestionnairesExposure-Response Analysis of Etrolizumab in Patients with Moderately-to-severely Active Ulcerative ColitisA Model-Based Longitudinal Meta-Analysis of FEV1 in Randomized COPD Trials